MEDICINE DETAILS
Zejula
Active ingredient: Niraparib
Neutral reference profile for an independent medicine-access consultancy enquiry about Zejula (Niraparib). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Zejula used for?
Zejula (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
It is available in capsule form, each containing 100mg niraparib.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Zejula identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
100 mg · 56 tablets Catalogue organisation: GlaxoSmithKline GmbH & Co. KG
-
100 mg · 84 tablets Catalogue organisation: GlaxoSmithKline GmbH & Co. KG
OFFICIAL SOURCES
Check the Zejula record at an official source.
Search for “Zejula” or “Niraparib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Zejula.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Zejula
01What is Zejula?＋
This directory record associates the brand name Zejula with the active ingredient Niraparib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Zejula strengths and packs are recorded?＋
The catalogue currently shows: 100 mg · 56 tablets; 100 mg · 84 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Zejula?＋
Catalogue records currently name: GlaxoSmithKline GmbH & Co. KG. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Zejula?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Zejula, payment request, stock guarantee or binding offer.
06Can I buy Zejula from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.